Marisa Wexler, MS,  senior science writer—

A modified version of the inflammatory protein TRAIL might be able to reverse fibrosis in scleroderma and related conditions, a study suggests. The study, titled “Targeting of dermal myofibroblasts through death receptor 5 arrests fibrosis in mouse models of scleroderma,” was published in the journal Nature…

The Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) has recommended — via a 10-7 vote — the approval of Ofev (nintedanib) for the treatment of systemic sclerosis-associated interstitial lung disease (SSc-ILD). Ofev, marketed by Boehringer Ingelheim, is…

Older age, active digital ulcers, lung tissue scarring, muscle weakness, and increased levels of C-reactive protein (CRP) are predictive factors of progressive organ damage in people with systemic sclerosis (SSc), a study has found. Taking these factors into consideration may help clinicians to identify patients at risk of SSc worsening,…